BiotechTube

Satralizumab + Placebo + Baseline Treatment

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neuromyelitis Optica (NMO)

Conditions

Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)

Trial Timeline

Feb 20, 2014 → Dec 23, 2021

NCT ID
NCT02028884

About Satralizumab + Placebo + Baseline Treatment

Satralizumab + Placebo + Baseline Treatment is a phase 3 stage product being developed by Chugai Pharmaceutical for Neuromyelitis Optica (NMO). The current trial status is completed. This product is registered under clinical trial identifier NCT02028884. Target conditions include Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD).

What happened to similar drugs?

2 of 5 similar drugs in Neuromyelitis Optica (NMO) were approved

Approved (2) Terminated (1) Active (3)
✅Satralizumab 120 mgChugai PharmaceuticalApproved
🔄Satralizumab + PlaceboChugai PharmaceuticalPhase 3
🔄satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroidsRochePhase 3
🔄SatralizumabRochePhase 3
✅InebilizumabAmgenApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02028884Phase 3Completed

Competing Products

8 competing products in Neuromyelitis Optica (NMO)

See all competitors
ProductCompanyStageHype Score
Satralizumab 120 mgChugai PharmaceuticalApproved
35
Satralizumab + PlaceboChugai PharmaceuticalPhase 3
40
satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroidsRochePhase 3
40
SatralizumabRochePhase 3
47
UPLIZNAAmgenPre-clinical
33
InebilizumabAmgenPhase 2
42
InebilizumabAmgenApproved
47
intravenous methylprednisoloneBrain BiotechPre-clinical
23